摘要
目的 为提高难治复发性急性白血病（ＲＲＡＬ）的治疗效果。方法应用威猛（ＶＭ２６）联合三尖杉酯硷和阿糖胞苷组成ＨＡＶ方案及威猛联合米托蒽琨组成ＭＶ方案治疗２１例ＲＲＡＬ。结果完全缓解（ＣＲ）率为５７．１％（１２／２１），总有效率为８５．７％（１８／２１）。其中难治复发性急性淋巴细胞白血病（ＡＬＬ）ＣＲ率为５０％，总有效率为７５％；难治复发性急性非淋巴细胞白血病（ＡＮＬＬ）ＣＲ率５８．８％，总有效率８８．２％。其主要毒副作用为骨髓抑制，但绝大部分病例经过间歇期后均能恢复。结论威猛联合化疗对难治复发ＡＬＬ和ＡＮＬＬ均有较好疗效。
Objective TO improve the efficacy in the therapeutic efficacy of Teniposide (Vin26) based combination chemotherapy forrefractory and relapsed acute leukemia. Methods MV regimen (Vin26 and MIT) and HAV regimen (Vm 26, Har and Ara-c) wereused to treat 21 refractory adult acute leukemia. Results The complete remission (CR) rate was 57.1% (12/21), and the totalremission (TR) rate was 85.7% (18/21 ). In the treatment of reftactory and relapsed acute lymphoblastic leukemia (ALL), the CR ratewas 50% (2/4), and the TR rate 75% (3/4). In the treatment of refractory and relapsed acute nonlymphoblastic leukemia (ANLL), theCR rate was 58.8% (10/1 7), and the TE rate 88.2% (15/17). The side effect of the regimens was arrest of bone marrow, but mostly ofthe patients recovered after intermission. Conclusion Vin26-based combination chemotherapy has good therapeutic efficacy for boththe refractory and relapsed ALL and refractory and relapsed ANLL.
出处
《第一军医大学学报》
CSCD
1999年第1期42-43,共2页
Journal of First Military Medical University
关键词
白血病
急性
RRAL
威猛方案
药物疗法
leukemia refractory and relapsed
chemotherapy
teniposide (Vm26)
